

Dosing Tool for your PDA
To use with your patients
[CLICK HERE TO DOWNLOAD](#)



Seroquel[®]
quetiapine fumarate
25 mg, 100 mg, 200 mg & 300 mg tablets

Advertisement



The NEW ENGLAND JOURNAL of MEDICINE

[HOME](#) | [SEARCH](#) | [CURRENT ISSUE](#) | [PAST ISSUES](#) | [COLLECTIONS](#) | [HELP](#)

Current Issue

- ▶ [Table of Contents](#)
- ▶ [Editors' Summaries](#)

For Subscribers

- ▶ [Activate Subscription Access](#)
- ▶ [Renew Subscription](#)
- ▶ [Pay My Bill](#)
- ▶ [CiteTrack](#)
- ▶ [Personal Archive](#)
- ▶ [PDA Services](#)
- ▶ [Teaching Tools](#)


Services

- ▶ [Subscribe](#)
- ▶ [Register for Free Access](#)
- ▶ [E-mail Table of Contents](#)
- ▶ [CME – Continuing Medical Education](#)
- ▶ [Institution Center](#)
- ▶ [Customer Services](#)
- ▶ [My Preferences](#)
- ▶ [Career Center – Physician Jobs](#)
- ▶ [Article Reprint Service](#)

For Authors and Reviewers

CURRENT ISSUE: October 30, 2003

SELECTED ARTICLES



[Fondaparinux for Pulmonary Embolism](#)

This pentasaccharide was as effective and safe as heparin.

[Ximelagatran vs. Warfarin](#)


A thrombin inhibitor to prevent thrombosis.

[Prevention of Venous Thromboembolism](#)

Ximelagatran to prevent recurrent thromboembolism.

[Mutations in Parathyroid Carcinoma](#)

Germline mutations of *HRPT2* in sporadic cases.



[The Toxicology of Mercury](#)

The facts and the controversies.

ALSO IN THIS ISSUE

PERSPECTIVE

[HRPT2 and Parathyroid Cancer](#)

[Tools of the Trade](#)

EDITORIAL

[Treating Thrombosis](#)

EARLY RELEASE

Posted October 9, 2003

▶ [Letrozole for Breast Cancer](#)

[Genomic Medicine Series](#)

▶ [Free Full Text](#)

SEARCH

Search the *Journal*

- ▶ [Advanced Search](#)
- ▶ [Search Medline](#)

IMAGE OF THE WEEK

[Bony Ghosts](#)

- ▶ [Help for Authors](#)
 - ▶ [Submit a Manuscript](#)
 - ▶ [Submit a Letter](#)
 - ▶ [PaperTRAIL](#)
 - ▶ [E-Review](#)
- About NEJM**
- ▶ [Online Tour](#)
 - ▶ [Editors and Publishers](#)
 - ▶ [Permissions Information](#)
 - ▶ [Editorial Policies](#)
 - ▶ [Advertising Policies](#)
 - ▶ [Privacy Policies](#)
- Help**
- ▶ [Contact us](#)
 - ▶ [FAQs](#)

SOUNDING BOARD

[Can We Prevent Cerebral Palsy?](#)

.....

The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice. Material is published with an emphasis on internal medicine and specialty areas including [allergy/immunology](#), [cardiology](#), [endocrinology](#), [gastroenterology](#), [hematology](#), [kidney disease](#), [oncology](#), [pulmonary disease](#), [rheumatology](#), [HIV](#), and [infectious diseases](#).

NEJM Online contains both the [current issue](#) and an [online archive](#) that can be accessed through [browsing](#), [advanced searching](#), or [collections by disease or topic](#). Subscriber services include [PDA content access](#), [teaching tools](#), and [continuing medical education \(CME\)](#).

.....

For faster access to NEJM Online from these areas use this URL:

<http://intl-content.nejm.org>

Australia, Brazil, China, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, Mexico, Russia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, The Netherlands, UK. ([More Information](#))

Free access for lower-income countries
([More Information](#))



A 16-year-old boy with back pain and an unusual history.

- ▶ [Recent Featured Images](#)
- ▶ [15 Most Recent Review Articles](#)
- ▶ [Journal Archives from 1993 to the Present](#)
- ▶ [Volume Index](#)

COLLECTIONS

Subject

- ▶ [Browse All Collections](#)
- ▶ [Browse Weekly CME](#)

The New England Journal of Medicine is owned, published, and [copyrighted](#) ©2003 [Massachusetts Medical Society](#).

All rights reserved. Electronic ISSN 1533-4406 Print ISSN 0028-4793

Editorial Offices: 10 Shattuck Street, Boston, MA 02115-6094 Phone: (617) 734-9800 FAX: (617) 739-9864

Business Offices: 860 Winter Street, Waltham, MA 02451-1413 Phone: (781) 893-3800 (x5515) (800) 843-6356 FAX: (781) 893-0413

[Terms and conditions for site use](#)

[HOME](#) | [SEARCH](#) | [CURRENT ISSUE](#) | [PAST ISSUES](#) | [COLLECTIONS](#) | [HELP](#)



www.nejmjobs.org



Advertisement



The NEW ENGLAND JOURNAL of MEDICINE

[HOME](#) | [SEARCH](#) | [CURRENT ISSUE](#) | [PAST ISSUES](#) | [COLLECTIONS](#) | [HELP](#)

[Sign up for the Table of Contents by e-mail](#)

TABLE OF CONTENTS

[◀ Previous](#)

Volume 349

October 30, 2003

Number 18

THIS WEEK IN THE JOURNAL

Article Summaries

[Summaries](#) | [PDF](#)

ORIGINAL ARTICLES

[Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism](#)

The Matisse Investigators

[Abstract](#) | [Full Text](#) | [PDF](#) | [CME Exam](#)

[Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement](#)

C. W. Francis and Others

[Abstract](#) | [Full Text](#) | [PDF](#)

[Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran](#)

S. Schulman and Others

[Abstract](#) | [Full Text](#) | [PDF](#)

[Somatic and Germ-Line Mutations of the *HRPT2* Gene in Sporadic Parathyroid Carcinoma](#)

T. M. Shattuck and Others

[Abstract](#) | [Full Text](#) | [PDF](#)

[[All Recent Original Articles](#)]

PERSPECTIVE

[HRPT2, a Marker of Parathyroid Cancer](#)

L. S. Weinstein and W. F. Simonds

[Extract](#) | [Full Text](#) | [PDF](#)

Tools of the Trade

D. Ofri

[Extract](#) | [Full Text](#) | [PDF](#)

[[All Recent Perspective Articles](#)]

EDITORIALS

[Treating Thrombosis in the 21st Century](#)

S. S. Shapiro

[Extract](#) | [Full Text](#) | [PDF](#)

[[All Recent Editorials](#)]

SOUNDING BOARD

[Can We Prevent Cerebral Palsy?](#)

K. B. Nelson

[Extract](#) | [Full Text](#) | [PDF](#)

[[All Recent Sounding Board Articles](#)]

IMAGES IN CLINICAL MEDICINE

[Cerebral Venous Thrombosis](#)

P.-M. Roy and E. Gras

[Extract](#) | [Full Text](#) | [PDF](#)

REVIEW ARTICLES

Current Concepts: The Toxicology of Mercury —

Current Exposures and Clinical Manifestations

T. W. Clarkson, L. Magos, and G. J. Myers

[Extract](#) | [Full Text](#) | [PDF](#) | [CME Exam](#)

Drug Therapy: Schizophrenia

R. Freedman

[Extract](#) | [Full Text](#) | [PDF](#) | [CME Exam](#)

[[All Recent Review Articles](#)]

Bony Ghosts — Residual Effects of Severe Growth

Arrest

J. Pfortner and M. Hövel

[Extract](#) | [Full Text](#) | [PDF](#)

[[All Recent Images](#)]

**CASE RECORDS OF THE
MASSACHUSETTS GENERAL HOSPITAL**

**Case 34-2003 — A 45-Year-Old Woman with a
Family History of Colonic Polyps and Cancer**

D. C. Chung, M. Mino, and K. M. Shannon

[Extract](#) | [Full Text](#) | [PDF](#)

[[All Recent Case Records](#)]

CORRESPONDENCE

Enfuvirtide, an HIV-1 Fusion Inhibitor

[Extract](#) | [Full Text](#) | [PDF](#)

**Bacterial Meningitis in Children with Cochlear
Implants**

[Extract](#) | [Full Text](#) | [PDF](#)

**Aortic Stenosis, von Willebrand Factor, and
Bleeding**

[Extract](#) | [Full Text](#) | [PDF](#)

Microsatellite Instability in Colon Cancer

[Extract](#) | [Full Text](#) | [PDF](#)

**Long-Term Outcomes after Successful Early
Defibrillation**

[Extract](#) | [Full Text](#) | [PDF](#)

**Patients Who Refuse Food and Fluids to Hasten
Death**

[Extract](#) | [Full Text](#) | [PDF](#)

Hogwarts Headaches — Misery for Muggles

[Extract](#) | [Full Text](#) | [PDF](#)

[[All Recent Correspondence](#)]

BOOK REVIEWS

Ovarian Cancer

[Extract](#) | [Full Text](#) | [PDF](#)

**Seeds of Mortality: The Public and Private Worlds
of Cancer**

[Extract](#) | [Full Text](#) | [PDF](#)

Fulfilling the Potential of Cancer Prevention and Early Detection

[Extract](#) | [Full Text](#) | [PDF](#)

[[All Recent Book Reviews](#)]

CORRECTIONS

Binge Eating as a Phenotype of Melanocortin 4 Receptor Gene Mutations

[Extract](#) | [Full Text](#) | [PDF](#)

[HOME](#) | [SEARCH](#) | [CURRENT ISSUE](#) | [PAST ISSUES](#) | [COLLECTIONS](#) | [HELP](#)

Comments and questions? Please [contact us](#).

The New England Journal of Medicine is owned, published, and [copyrighted](#) © 2003 [Massachusetts Medical Society](#). All rights reserved.

Long-Term Outcomes after Successful Early Defibrillation

TO THE EDITOR: Bunch and colleagues (June 26 issue)¹ note that the quality of life of survivors after out-of-hospital cardiac arrest was, in most respects, similar to that of the general population. Patients who have undergone treatment after a life-threatening event or who have undergone major surgery may and often do have anxiety or depression months to years after the event.² Moreover, the effects of drugs on the quality of life of patients with cardiovascular diseases are important considerations for health care professionals.^{3,4} One limitation of this study that should be addressed is the possible use by the patients of anxiolytic agents, antidepressants, or other medications, including antihypertensive drugs, which can affect their responses to the Medical Outcomes Study 36-Item Short-Form General Health Survey.

Nicola C. Ho, M.D.

National Institutes of Health
Baltimore, MD 21224
honi@grc.nia.nih.gov

1. Bunch TJ, White RD, Gersh BJ, et al. Long-term outcomes of out-of-hospital cardiac arrest after successful early defibrillation. *N Engl J Med* 2003;348:2626-33.
2. Rymaszewska J, Kiejna A, Hadryg T. Depression and anxiety in coronary artery bypass grafting patients. *Eur Psychiatry* 2003;18:155-60.
3. Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. *N Engl J Med* 1986;314:1657-64.
4. Wenger NK, Mattson ME, Furberg CD, Elinson J. Assessment of quality of life in clinical trials of cardiovascular therapies. *Am J Cardiol* 1984;54:508-13.

THE AUTHORS REPLY: We agree with Dr. Ho that both anxiety and depression are associated with an adversely affected quality of life after cardiac events.¹ In addition, depression is a long-term risk factor in patients with cardiac disease — in particular, after myocardial infarction — for recurrent cardiovascular events and death.^{2,3} It is uncertain whether antidepressive therapy will improve cardiac outcomes in patients with depression after myocardial infar-

tion.³ Antihypertensive therapy may also have effects on the quality of life, which may vary within populations.^{4,5}

In our study, 3 of 79 neurologically intact survivors of out-of-hospital cardiac arrest (4 percent) were discharged while receiving antidepressant therapy, and no patient was receiving an anxiolytic agent. The use of antihypertensive medications was prevalent at hospital discharge (beta-blockers in 43 patients [54 percent], angiotensin-converting-enzyme inhibitors in 37 patients [47 percent], angiotensin-receptor blockers in 2 patients [3 percent], calcium-channel blockers in 6 patients [8 percent], and diuretics in 16 patients [20 percent]). We do not have data on the frequency of use of these medications at the time that quality of life was evaluated. Careful assessment for depression and anxiety should be part of the evaluation of all patients with cardiovascular events. Potential side effects of therapy targeted to risk factors must be weighed in the context of the long-term benefits.

T. Jared Bunch, M.D.

Roger D. White, M.D.

Douglas L. Packer, M.D.

Mayo Clinic
Rochester, MN 55905
white.roger@mayo.edu

1. Sullivan MD, LaCroix AZ, Spertus JA, Hecht J. Five-year prospective study of the effects of anxiety and depression in patients with coronary artery disease. *Am J Cardiol* 2000;86:1135-8.
2. Carney RM, Rich MW, Freedland KE, et al. Major depressive disorder predicts cardiac events in patients with coronary artery disease. *Psychosom Med* 1988;50:627-33.
3. van den Brink RH, van Melle JP, Honig A, et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial Infarction and Depression-Intervention Trial (MIND-IT). *Am Heart J* 2002;144:219-25.
4. Fletcher AE, Bulpitt CJ, Thijs L, et al. Quality of life on randomized treatment for isolated systolic hypertension: results from the Syst-Eur Trial. *J Hypertens* 2002;20:2069-79.
5. Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. *N Engl J Med* 1986;314:1657-64.

Patients Who Refuse Food and Fluids to Hasten Death

TO THE EDITOR: The results from the study by Ganzi et al. (July 24 issue)¹ were certainly thought provoking. However, it would have been interesting to learn how family members perceived the quality of the deaths of these patients. Physicians and nurses often underestimate the amount of pain that pa-

tients report² and may also underestimate the distress of the dying.

A recent article in the *New York Times* gave anecdotal evidence that family members may perceive these deaths differently.³ Jane Gross describes the death of her mother in a nursing home after she had

refused food and hydration. She reports initially encountering obstacles to the effective relief of symptoms that were attributable primarily to restrictions on the dispensation of narcotics.

Supreme Court Justice John Paul Stevens, in a concurring opinion in *Vacco v. Quill*, found that although there was no constitutional right to assisted suicide, a person did have an interest in “choosing a final chapter that accords with her life story, rather than one that demeans her values and poisons memories of her.”⁴ It behooves us as medical professionals to work with patients and families to ensure that such choices can be made.

Rebecca A. Drayer, M.D.

University of Pittsburgh
Pittsburgh, PA 15213

1. Ganzini L, Goy ER, Miller LL, Harvath TA, Jackson A, Delorit MA. Nurses' experience with hospice patients who refuse food and fluids to hasten death. *N Engl J Med* 2003;349:359-65.
2. Drayer RA, Henderson J, Reidenberg MM. Barriers to better pain control in hospitalized patients. *J Pain Symptom Manage* 1999; 17:434-40.
3. Gross J. Striving for a gentle farewell. *New York Times*. August 3, 2003 (Section 4):1.
4. *Vacco v. Quill*, 117 Sup. Ct. 2293 (1997).

TO THE EDITOR: “Freedom,” the writer James Baldwin remarked in 1961, “is not something that anybody can be given; freedom is something people take.” The freedom to take one’s life, in this case through starvation and dehydration, is not something that a physician, nurse, or caregiver can give to a patient who wants to die. Moreover, a patient’s reasons for wanting to die are private, not public.

A physician cannot give “permission” for a patient to live or die, despite what Peter Reagan says in the Perspective article by Jacobs that accompanies the report by Ganzini et al.¹ Ganzini et al. describe patients who want to die and note that “unbearable physical suffering did not appear to be an important reason for this choice.” The authors qualify this “choice” as a possible symptom of depression.

These are ethical matters, not medical ones, and they lie beyond the physician’s expertise as a medical practitioner.^{2,3} A physician respects a patient’s request for drugs to help him or her feel comfortable or disrespects and rejects such requests. The values and autonomy of the patient are the critical issues here, not the values and authority of the physician.

Jeffrey A. Schaler, Ph.D.

American University
Washington, DC 20016
jeffschaler@attglobal.net

1. Jacobs S. Death by voluntary dehydration — what the caregivers say. *N Engl J Med* 2003;349:325-6.
2. Schaler JA. Living and dying the state’s way. *Liberty* 2003;17(8): 42-4.
3. Szasz TS. *Fatal freedom: the ethics and politics of suicide*. Westport, Conn.: Praeger, 1999.

THE AUTHORS REPLY: There are important exceptions to the statements made by Schaler. If a mental illness such as depression, delirium, or dementia renders a patient unable to understand and appreciate the risks, benefits, and alternatives to the choice to stop food and fluids, the choice may reflect the patient’s incompetence. Decisions made during an episode of depression may not be autonomously made. Medical professionals are obligated to assess the patient’s decision-making capacity and participate in legal interventions that may result in overriding the patient’s choice.

Schaler may not agree with the legal, medical, or philosophical basis for the prevention of suicide, but most states have laws that allow, in some situations, the forcible and even public prevention of suicide, which may include at least the temporary hydration of a patient against his or her will.¹ Admittedly, clinicians should pause and seek knowledgeable counsel if they are ever considering taking legal steps to override the decision of a terminally ill patient to hasten death through the voluntary refusal of food and fluids, even if the patient is depressed. Furthermore, all will fare better if the clinician uses empathy and good clinical skills to address the patient’s needs in a way that allows him or her to maintain an alliance with the patient.

We disagree with Schaler’s opinion that these matters are not medical and are beyond the physician’s expertise. Many patients avidly seek information about their options when faced with a poor prognosis. The physician is often the first and sometimes the only source of information about palliative treatments and other choices that may be pursued. Physicians must be well informed about these options, including the refusal of food and fluids, in order to provide optimal care for patients at the end of life.

We agree with Drayer that our study, an initial attempt to understand the voluntary refusal of food and fluids, is by no means definitive and should be followed by studies involving patients who are in the process of making these choices and examining the views and experiences of the families of patients who choose to hasten death in this manner.

Linda Ganzini, M.D., M.P.H.
Elizabeth Goy, Ph.D.
Oregon Health and Science University
Portland, OR 97239


1. Gutheil TG, Appelbaum PS. Clinical handbook of psychiatry and the law. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2000.

Hogwarts Headaches — Misery for Muggles

TO THE EDITOR: During the past several months, I have evaluated three children between 8 and 10 years of age who presented with a two-to-three-day history of generalized headaches. In each case, the headache was dull and the pain fluctuated throughout the day. One patient also reported neck and wrist pain. All the patients were afebrile and free of any symptoms suggesting an underlying infectious or neurologic cause. On further questioning, it was determined that each child had spent many hours reading J.K. Rowling's latest book in the Harry Potter series. Two patients read the book lying prone, and the third propped the book on her legs and rested her head on a pillow.

The presumed diagnosis for each child was a tension headache brought on by the effort required to plow through an 870-page book. The obvious cure for this malady — that is, taking a break from reading — was rejected by two of the patients, who preferred acetaminophen instead. In all cases, the pain resolved one to two days after the patient had finished the book.

It is worth noting that I did not witness this phenomenon with any of the previous Harry Potter tomes and that each of Rowling's successive books has been bigger than the last (Fig. 1). If this esca-



tion continues as Rowling concludes the saga, there may be an epidemic of Hogwarts headaches in the years to come.

Howard J. Bennett, M.D.

George Washington University Medical Center
Washington, DC 20037

Correspondence Copyright © 2003 Massachusetts Medical Society.

INSTRUCTIONS FOR LETTERS TO THE EDITOR

Letters to the Editor are considered for publication, subject to editing and abridgment, provided they do not contain material that has been submitted or published elsewhere. Please note the following: •Letters in reference to a *Journal* article must not exceed 175 words (excluding references), must be received within three weeks after publication of the article, and must be submitted over the Internet at secure.nejm.org/letters. Letters not related to a *Journal* article must not exceed 400 words and may be submitted over the Internet or sent, typewritten and triple-spaced, by mail. •A letter can have no more than five references and one figure or table. •A letter can be signed by no more than three authors. •Financial associations or other possible conflicts of interest must be disclosed. (Such disclosures will be published with the letters. For authors of *Journal* articles who are responding to letters, this information appears in the original articles.) •Include your full mailing address, telephone number, fax number, and e-mail address with your letter.

Our address: **Letters to the Editor • New England Journal of Medicine • 10 Shattuck St. • Boston, MA 02115**

Our Web address: secure.nejm.org/letters

Our fax numbers: **617-739-9864** and **617-734-4457**

We cannot acknowledge receipt of your letter, but we will notify you when we have made a decision about publication. Letters that do not adhere to these instructions will not be considered. Rejected letters and figures will not be returned. We are unable to provide prepublication proofs. Submission of a letter constitutes permission for the Massachusetts Medical Society, its licensees, and its assignees to use it in the *Journal's* various print and electronic publications and in collections, revisions, and any other form or medium.